Abendstein B, Marth C, Daxenbichler G
Department of Obstetrics and Gynecology, University of Innsbruck, Austria.
Clin Chim Acta. 1987 Sep 15;168(1):47-54. doi: 10.1016/0009-8981(87)90265-8.
RU-27987, a synthetic progestin, which was recently developed by Roussel Uclaf, Paris, was tested for its validity as a ligand to determine the progesterone receptor in breast cancer. The results were compared to those obtained with R-5020 and ORG-2058, two ligands that are already in use worldwide. The intra- and interassay variation of receptor determination was similar for all 3 ligands. Receptor levels were analyzed with each of the 3 progestins in control cytosols and in 26 mammary carcinoma samples. A good correlation between receptor levels was found although the values of ORG-2058 were somewhat lower, but not significantly. This resulted in a lower proportion of receptor positive samples for ORG-2058 (11/26) compared to R-5020 (13/26) and RU-27987 (14/26). The affinity to the progesterone and to the glucocorticoid receptor, as well as the precision of the Scatchard plot analysis were comparable for the 3 ligands tested. Intra- and interassay variation of receptor determination were also similar. We therefore conclude, that RU-27987 is a suitable ligand to determine progesterone receptor in mammary carcinoma.
RU - 27987是一种合成孕激素，由巴黎的罗素·优克福公司（Roussel Uclaf）最近研发，作为一种配体，其测定乳腺癌中孕激素受体的有效性经过了测试。研究结果与使用R - 5020和ORG - 2058这两种已在全球范围内使用的配体所获得的结果进行了比较。三种配体在受体测定中的批内和批间变异相似。分别使用这三种孕激素对对照胞质溶胶和26份乳腺癌样本的受体水平进行了分析。尽管ORG - 2058的值略低，但受体水平之间存在良好的相关性，但差异不显著。与R - 5020（13/26）和RU - 27987（14/26）相比，ORG - 2058的受体阳性样本比例较低（11/26）。三种受试配体对孕激素和糖皮质激素受体的亲和力以及Scatchard图分析的精度相当。受体测定的批内和批间变异也相似。因此，我们得出结论，RU - 27987是测定乳腺癌中孕激素受体的合适配体。
